<DOC>
	<DOCNO>NCT01666418</DOCNO>
	<brief_summary>This open , monocentric , pilot study determine metabolic activity ( glucose-uptake ) vivo monotherapy pazopanib comparison combination therapy pazopanib plus paclitaxel investigate transcriptional profile cutaneous melanoma metastasis therapy ( pazopanib vs. pazopanib plus paclitaxel ) subject unresectable Stage III Stage IV melanoma receive prior cytotoxic chemotherapy . Primary Objective : Evaluation metabolic activity vivo Secondary Objective : Determination change gene expression profile Evaluation antitumor activity combination term progression free survival ( PFS ) . Changes S100 LDH therapy time point FDG-PET/CT ( combine serum measurement S100 LDH ) - Trial medicinal product</brief_summary>
	<brief_title>Pilot Study Investigating Metabolic Activity Transcriptional Profiling Vivo Tumor Biopsies Melanoma Patients During Treatment With Pazopanib Alone Combination With Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Age â‰¥ 18 year Diagnosis histologically cytologically confirm melanoma stage III IV . Fresh tumor tissue must provide subject biomarker analysis ( within 14 day prior treatment start ) ( day 10 pazopanib monotherapy last day treatment pazopanib , day 70 ) treatment investigational product ( asservation RNAlater , kryo asservation , cell culture ) Assessable metastasis ( skin superficial lymph node minimal diameter 1 cm ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate organ system function Exclusion criterion : Prior malignancy . Central nervous system ( CNS ) metastases Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting ; Myocardial infarction ; Unstable angina ; Coronary artery bypass graft surgery ; Symptomatic peripheral vascular disease ; Class III IV congestive heart failure , define New York Heart Association ( NYHA ) . Poorly control hypertension History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Presence uncontrolled infection Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding Evidence active bleeding bleed diathesis Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia . Prior exposure study drug pazopanib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>